The PI4K IIIα inhibitor radiosensitized tumor cells by modulating PI3Kδ and regulated the immune response by regulating PD-L1 expression and affecting the CD4(+)/CD8(+) ratio of T lymphocyte. The gene discussed is CD274; the disease is neoplasm.